Cytokinetics analyst coverage
WebCytokinetics was founded by pioneers in the field of muscle biology. This team of forward-thinking scientists set out a vision for translating their expertise into new insights and approaches to novel drug discovery. WebFintel reports that on April 13, 2024, Baird initiated coverage of Pliant Therapeutics (NASDAQ:PLRX) with a Outperform recommendation. Analyst Price Forecast Suggests 80.40% Upside As of April 6 ...
Cytokinetics analyst coverage
Did you know?
WebMar 31, 2024 · SOUTH SAN FRANCISCO, Calif., March 31, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Data Monitoring … Web1 day ago · Cytokinetics Presents Positive Results From Cohort 4 of REDWOOD-HCM and Long-Term Results From FOREST-HCM at the American College of Cardiology 72nd …
WebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. Investors & Media. ... Analyst Coverage. Investor FAQ. IR/Media Contacts. Corporate Governance. Information Request . Email Alerts . WebShare This: Share 2024 – Summer Analyst Internship – Financial Institutions Coverage (FIC) on Facebook Share 2024 – Summer Analyst Internship – Financial Institutions ... Financial Institutions Coverage (FIC) manages relationships with the bank’s largest institutional clients across key sectors: banks, hedge funds, asset managers ...
WebMar 7, 2024 · Cytokinetics (CYTK) Analysts Prediction, Stock Forecast & Price Targets - Simply Wall St View Valuation Cytokinetics Future Growth Future criteria checks 0/6 Cytokinetics, Incorporated's earnings is forecasted to decline at 23.5% and its revenue is expected to decline at 46.6%. WebFeb 27, 2024 · Cytokinetics, Incorporated (NASDAQ:CYTK - Get Rating) has earned a consensus rating of "Moderate Buy" from the fifteen brokerages that are presently covering the stock, Marketbeat.com reports.One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and seven have given a buy …
WebApr 9, 2024 · CYTK has been the topic of a number of recent analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $58.00 target price on shares of Cytokinetics in a research note on ...
WebMar 3, 2024 · Following the latest upgrade, the current consensus, from the 13 analysts covering Cytokinetics, is for revenues of US$54m in 2024, which would reflect a stressful 43% reduction in... onum wp themeWebApr 2, 2024 · Financials. In 2024, Cytokinetics reported revenues of $2.0 million for Q4 and $94.6 million for the full year, compared to $55.6 million and $70.4 million in the same periods of 2024. This ... iotex price todayWebApr 11, 2024 · What analysts cover Cytokinetics? Cytokinetics has been rated by Bank of America, Cantor Fitzgerald, HC Wainwright, JMP Securities, Mizuho, Needham & Company LLC, Oppenheimer, The Goldman Sachs Group, and UBS Group in the past 90 days. Stock Ratings Reports and Tools Top-Rated Brokerages Stock Ratings Screener Free Ratings … iot expo olympiaWeb12 hours ago · Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cytokinetics ( CYTK – Research Report) and Neurocrine ( … iotex to usdWebSep 28, 2024 · Cytokinetics Incorporated CYTK Competitors News Profile Analyst Coverage 5 Yr. Financials Dividends Adv. Charts Earnings Options Price History Events Insiders Cytokinetics Incorporated News... iot expo north america 2022WebMar 1, 2024 · SOUTH SAN FRANCISCO, Calif., March 01, 2024(GLOBE NEWSWIRE) -- Cytokinetics, Incorporated(Nasdaq: CYTK) reported financial results for the fourth … iot expo 2022 californiaWebJan 9, 2024 · By contrast, our data suggests that other companies (with analyst coverage) in the industry are forecast to see their revenue grow 14% per year. ... We have analyst estimates for Cytokinetics ... onuncheck